Inventor · disambiguated record
Xiaohong He
Also filed as: HE XIAOHONG
4 granted patents·15 pending applications·30 citations·filing 2009–2024
70Inventor score
Files withNANJING BIOHENG BIOTECH CO LTD8BIOHENG THERAPEUTICS LTD7HE XIAOHONG1INST OF ANIMAL SCIENCES OF CAAS1LI DAPING1
Top patents by PatentIndex Score
19 records- 0186USD964772SPaper towel holderTONGXIANG GUIZHENG TRADE CO LTD·Filed 2022·Granted Sep 27, 2022·26 cites·1 claims
- 0277US11896620B2Engineered immune cell and use thereofNANJING BIOHENG BIOTECH CO LTD·Filed 2021·Granted Feb 13, 2024·1 cites·22 claims
- 0361US8399237B2Pseudomonas alcaliphila MBR and its application in bioreduction and biosorptionLI DAPING·Filed 2009·Granted Mar 19, 2013·1 cites·20 claims
- 0455US2025122583A1Sheep single nucleotide polymorphism (snp) molecular marker and use thereof in detecting resistance to brucellosis in sheepINST OF ANIMAL SCIENCES OF CAAS·Filed 2024·Application pending·0 cites
- 0554US8645519B2Method for interacting messages based on simple network management protocolHE XIAOHONG·Filed 2010·Granted Feb 4, 2014·2 cites·17 claims
- 0652US2023399398A1Cd7-targeting humanized antibody and use thereofBIOHENG THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 0752US2023390336A1Chimeric antigen receptor targeting cd7 and use thereofBIOHENG THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 0851US2024018236A1Cd19-targeting humanized antibody and use thereofBIOHENG THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 0951US2024052029A1Ror1-targeting antibody and use thereofBIOHENG THERAPEUTICS LTD·Filed 2022·Application pending·0 cites
- 1050US2024082306A1Novel chimeric antigen receptor and use thereofBIOHENG THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1150US2024043532A1Nkg2a-targeting antibody and use thereofBIOHENG THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1248US2024009308A1Chimeric antigen receptor comprising novel co-stimulatory domain and use thereofNANJING BIOHENG BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1348US2024009311A1Engineered immune cell and use thereofNANJING BIOHENG BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1448US2024018251A1Bcma-targeting single-domain antibody and use thereofBIOHENG THERAPEUTICS LTD·Filed 2021·Application pending·0 cites
- 1548US2023270858A1Novel co-stimulatory domain and use thereofNANJING BIOHENG BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1647US2023242661A1Engineered immune cell expressing nk inhibitory molecule and use thereofNANJING BIOHENG BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1746US2023248768A1Engineered immune cell for allotransplantationNANJING BIOHENG BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1846US2023242877A1Immune cell comprising chimeric antigen receptor and use thereofNANJING BIOHENG BIOTECH CO LTD·Filed 2021·Application pending·0 cites
- 1941US2020377878A1Modified t cells and uses thereofNANJING BIOHENG BIOTECH CO LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Xiaohong He files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →